Variman Global approves ₹191 cr Ecogenics swap in 2026

Board clears two major proposals on August 29, 2026

Variman Global Enterprises Limited has approved two connected corporate actions: a share-swap acquisition and a fresh fund raise. The decisions were taken at the company’s Board of Directors meeting held on August 29, 2026. The acquisition is structured as a swap, while the capital raising plan is through preferential allotment and convertible warrants. Both proposals are subject to shareholder approval at the ensuing General Meeting. The company has also indicated timelines and key conditions for closing the acquisition.

Share-swap acquisition: 99.99% stake in Ecogenics

The board approved acquiring a 99.99% stake in Ecogenics Technologies and Systems Limited. The share-swap transaction is valued at ₹190.995 crore. As per the approval, the consideration will be discharged through issuance of Variman Global equity shares rather than cash. The company said there will be no cash outflow for Variman under this structure. The plan involves issuing up to 41,07,42,006 equity shares to five sellers of Ecogenics shares on a swap basis. The company expects the transaction to close within 12 months after shareholder approval.

Deal structure and key conditions

Variman’s proposal is a swap-based acquisition, which typically changes the equity base of the acquirer due to new share issuance. In this case, the issuance size is explicitly stated as up to 41,07,42,006 shares. The company has not indicated any cash consideration as part of the deal. The acquisition requires shareholder consent at the ensuing General Meeting. Completion is expected within 12 months of such approval, as per the company’s stated timeline. Since the issuance is to five sellers, the post-transaction shareholding structure may change, depending on final allotment and approvals.

Preferential issue and warrants: ₹25.91 crore fund raise

Alongside the acquisition, the board sanctioned a capital raise of ₹25.91 crore via preferential allotment and convertible warrants. The company stated the purpose as funding operations and supporting growth. Both instruments are priced at ₹4.65 per equity share. The plan splits the raise into two parts: a preferential allotment to non-promoter investors and warrants to promoters and non-promoters. The company also clarified the conversion window and forfeiture condition related to the warrants.

Preferential allotment: 1.67 crore shares to 29 investors

Under the preferential allotment, Variman approved issuing up to 1,67,32,245 equity shares. The issuance is proposed to 29 non-promoter investors. The aggregate amount for this allotment is ₹7.78 crore. The issue price is ₹4.65 per equity share, consistent with the overall pricing for the capital raise. This step, like the acquisition, requires shareholder approval before execution.

Convertible warrants: 3.90 crore warrants with an 18-month window

Variman also approved issuing up to 3,90,00,000 convertible warrants. These warrants are to be allotted to promoters and non-promoters, aggregating to ₹18.13 crore at the same price of ₹4.65 per equity share. The warrants can be converted into equity shares within 18 months. The company stated that any unconverted amounts will be forfeited. This condition is relevant for investors assessing dilution risk, because conversion would expand the equity base over time, while non-conversion would not.

Timeline of the latest decisions

The company’s disclosures also referenced earlier steps leading to the August 29, 2026 outcome. A fund raise proposal was dated August 24, 2026, ahead of the board’s approval. The acquisition decision was tagged as a strategic acquisition item dated August 29, 2026. The company had also indicated the board meeting would consider acquisitions of IT and digital transformation companies in India or abroad.

Earlier corporate actions provide context on capital strategy

The article content also lists earlier approvals that show Variman’s broader capital and acquisition approach. In an Extra Ordinary General Meeting held on March 14, 2024, shareholders approved issuing 6,90,30,000 convertible warrants at ₹20 per share, aggregating up to ₹138.06 crore. Later, on May 11, 2024, the board approved allotment of 2,69,80,000 convertible warrants to non-promoters at ₹20 per warrant. The text also references an amount of ₹13.49 crore as the 25% upfront amount in relation to the warrants.

In addition, an Extra Ordinary General Meeting held on July 5, 2025 approved raising of funds and issuance of securities through QIP and/or FCCB and/or other permissible modes. Separately, the company referenced a board approval to explore fund-raising options for an amount not exceeding USD 50 million (or equivalent) in one or more tranches, subject to approvals.

Past acquisition activity and share capital actions

Variman’s prior board outcomes included plans that mirror the share-swap approach used for the Ecogenics deal. A board meeting held on June 7, 2025 included approval to increase authorised share capital from ₹27 crore to ₹50 crore, subject to shareholder approval. The same meeting approved acquisition of a 76% stake in Cultnerds IT Solutions Private Limited on a swap basis through preferential allotment by issuing up to 32,37,600 Variman equity shares at an issue price of ₹10.50 per share. The total consideration for that acquisition was stated as ₹3.39948 crore. The disclosures also mention the deferment of some acquisition-related items to a subsequent meeting.

Market impact: what investors can infer from the stated numbers

Based on the disclosed structure, the Ecogenics transaction is explicitly a no-cash-outflow acquisition for Variman, funded through equity issuance. This can preserve cash but increases the share count, which matters for per-share metrics. The fund raise, if completed, would add equity immediately via preferential allotment and potentially later via warrant conversion. The warrant clause that unconverted amounts will be forfeited establishes a hard end date for conversion and limits open-ended dilution. Shareholder approval remains the key gating item for both the acquisition and the capital raise.

Why the approvals matter for the company’s near-term agenda

The simultaneous approval of an acquisition and a fund raise indicates that Variman is pursuing both inorganic expansion and balance sheet support. The company has explicitly linked the ₹25.91 crore proposal to funding operations and supporting growth. It has also previously discussed acquisitions in IT products and digital transformation sectors, including potential acquisitions in India or abroad. The next material milestone is the shareholder vote at the ensuing General Meeting, since both items require approval before implementation.

Conclusion

Variman Global Enterprises has approved a ₹190.995 crore share-swap acquisition of Ecogenics and a ₹25.91 crore preferential fund raise priced at ₹4.65 per share, with warrants convertible within 18 months. Both actions now move to shareholders for approval at the ensuing General Meeting. The company expects the Ecogenics transaction to close within 12 months of shareholder approval, and the funding plan will depend on the same consent process.